{"cluster": 36, "subcluster": 53, "abstract_summ": " Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, leads to significant mortality and morbidity . Increasing evidence for the use of an interleukin 6 (IL-6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context . Ruxolitinib (RXB), a JAK-STAT inhibitor, has proven efficacy in the treatment of sHLH ."}